Adam D Durbin
Overview
Explore the profile of Adam D Durbin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weichert-Leahey N, Shi H, Tao T, Oldridge D, Durbin A, Abraham B, et al.
bioRxiv
. 2023 Mar;
PMID: 36909587
Childhood neuroblastomas exhibit plasticity between an undifferentiated neural crest-like "mesenchymal" cell state and a more differentiated sympathetic "adrenergic" cell state. These cell states are governed by autoregulatory transcriptional loops called...
12.
Morita K, He S, Nowak R, Wang J, Zimmerman M, Fu C, et al.
Cell
. 2022 Aug;
185(16):3058.
PMID: 35931023
No abstract available.
13.
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
Shendy N, Zimmerman M, Abraham B, Durbin A
Cell Rep Med
. 2022 May;
3(5):100632.
PMID: 35584622
Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity...
14.
Hsu J, Danis E, Nance S, OBrien J, Gustafson A, Wessells V, et al.
Cell Rep
. 2022 Feb;
38(5):110323.
PMID: 35108532
Rhabdomyosarcoma (RMS) is a pediatric muscle sarcoma characterized by expression of the myogenic lineage transcription factors (TFs) MYOD1 and MYOG. Despite high expression of these TFs, RMS cells fail to...
15.
Durbin A, Wang T, Wimalasena V, Zimmerman M, Li D, Dharia N, et al.
Cancer Discov
. 2021 Nov;
12(3):730-751.
PMID: 34772733
Significance: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2β. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its...
16.
Zimmerman M, Durbin A, He S, Oppel F, Shi H, Tao T, et al.
Sci Adv
. 2021 Oct;
7(43):eabe0834.
PMID: 34669465
Neuroblastoma cell identity depends on a core regulatory circuit (CRC) of transcription factors that collaborate with to drive the oncogenic gene expression program. For neuroblastomas dependent on the adrenergic CRC,...
17.
De Wyn J, Zimmerman M, Weichert-Leahey N, Nunes C, Cheung B, Abraham B, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638267
Roughly half of all high-risk neuroblastoma patients present with MYCN amplification. The molecular consequences of MYCN overexpression in this aggressive pediatric tumor have been studied for decades, but thus far,...
18.
Neggers J, Paolella B, Asfaw A, Rothberg M, Skipper T, Yang A, et al.
Cell Rep
. 2021 Jul;
36(2):109367.
PMID: 34260938
No abstract available.
19.
Ohguchi H, Park P, Wang T, Gryder B, Ogiya D, Kurata K, et al.
Blood Cancer Discov
. 2021 Jul;
2(4):370-387.
PMID: 34258103
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3K4 trimethylation, a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and...
20.
Dharia N, Kugener G, Guenther L, Malone C, Durbin A, Hong A, et al.
Nat Genet
. 2021 Mar;
53(4):529-538.
PMID: 33753930
Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational-burden adult cancers. A key question, however, is whether functional genomic approaches will yield new targets in pediatric cancers, known...